Compare Moderna, Inc. (MRNA) vs Toyota Motor Corp (TM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs Toyota Motor Corp — how do they compare? Moderna, Inc. trades at $59.66 (market cap $23.60B), while Toyota Motor Corp trades at $179.51 (market cap $212.22B). The key difference: Toyota Motor Corp is far larger — about 9× Moderna, Inc.'s market cap, and Toyota Motor Corp pays a 3.51% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals.
| MRNA | TM | |
|---|---|---|
Market Cap | $23.60B | $212.22B |
Sector | Health | Consumer Cyclical |
52-Week High | $81.80 | $248.29 |
52-Week Low | $22.36 | $166.50 |
Enterprise Value | $19.70B | $376.42B |
Dividend Yield | — | 3.51% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $59.66, down 3.49% in the last session amid broader biotech volatility. The stock shows a mixed technical picture with bullish overall signals but bearish moving averages. Fundamentally, revenue has declined from pandemic peaks to $1.92B in 2025, with net losses widening to -$2.82B. Recent positive developments include an EU RSV vaccine contract and progress in cancer immunotherapy trials, with Q2 2026 earnings due July 31.
Outlook remains speculative as Moderna transitions beyond COVID-19 vaccines. Opportunities lie in its expanding pipeline in oncology and flu vaccines, but risks include sustained losses, competitive pressure, and execution hurdles. Analyst consensus is cautious with a $49 price target below current levels, reflecting uncertainty over profitability timeline.
Toyota Motor (TM) trades at $180.34, up 1.54% today, showing strong fundamental metrics with a P/E of 9.78 and consistent earnings beats. Technical indicators are neutral overall, with the stock near resistance at $182. Recent news highlights a $3.6 billion Texas plant expansion to shift Tacoma production from Mexico, signaling strategic US investment.
The outlook is positive given undervaluation signals and hybrid vehicle leadership, but risks include margin pressure from rising costs and competitive auto market dynamics. Analyst consensus is mixed with 37.5% buy ratings, suggesting cautious optimism amid macroeconomic uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About Toyota Motor Corp
Founded in 1937, Toyota is one of the world's largest automakers with 10.38 million units sold at retail in fiscal 2022 across its light vehicle brands. Brands include Toyota, Lexus, Daihatsu, and truck maker Hino.
Read more on TM →
